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Atrial ﬁbrillation (AF) has been reported to complicate the course of
acute myocardial infarction (AMI) in 6–21% of hospitalized
patients.
1 Possible precipitating factors of AF in this setting include
atrial ischaemia or infarction, right ventricular infarction, pericardial
inﬂammation, acute hypoxia or hypokalaemia, and haemodynamic
impairment secondary to left ventricular (LV) dysfunction.
2–4
Endogenous or exogenous catecholamines may also precipitate AF.
These factors can be found alone or in combination, and may super-
impose on predisposing diseases affecting cardiac anatomy and
physiology, such as previous cardiomyopathy, valvular impairment,
or chronic lung disease. Finally, AF in the setting of AMI has been
reported to be associated with ageing, severely impaired LV function,
presence of mitral regurgitation, or frequent ventricular arrhythmias
plus right bundle branch block, and presence of left bundle branch
block. Although most of these factors are claimed to be causative
of AF, the intimate relationship between their presence and AF
occurrence is not known. Despite the variability of factors and con-
ditions associated with AF in clinical practice, patients developing this
arrhythmia during AMI are usually reported as a uniform category.
AF can cause haemodynamic instability because of the rapid
ventricular rate, irregular ventricular ﬁlling, and/or loss of atrial
contribution to cardiac output,
5 ultimately leading to an increase
in oxygen demand. If deterioration of the haemodynamic balance
secondary to AF may intuitively affect pre-discharge outcome of
AMI victims, less intuitive is the association between AF in the
early phase of AMI and long-term outcome.
Schmitt et al. report on a clinical review evaluating the incidence,
clinical features, and prognostic implication of AF in AMI.
1 Through
this investigation, the authors provide a summary on clinically
relevant items such as identiﬁcation of clinical variables associated
with the development of AF and their prognostic implications, inci-
dence of in-hospital and post-discharge mortality in AF groups vs.
the remaining population, causes of death, impact of AF on stroke
risk, efﬁcacy of anticoagulation strategies, and treatment of AF
during AMI. Ageing, Killip class IV, heart rate at admission, and
pre-existing AF were consistently found to be strong independent
predictors in different trials; not unexpectedly, the prevalence of
patients presenting with these parameters, except for ageing,
appeared to decrease in most recent trials under the inﬂuence
of early reperfusion therapies, and use of b-blockers, angiotensin-
converting enzyme (ACE) inhibitors and angiotensin (AT) II inhibi-
tors. Also LV hypertrophy, probably as an indicator of increased
intracardiac pressure, was shown to be a signiﬁcant predictor,
whereas the ST-segment elevation myocardial infarction (STEMI)
vs. non-ST-segment elevation myocardial infarction (NSTEMI)
nature of myocardial damage did not appear to inﬂuence the pro-
pensity to develop in-hospital AF.
6 The presence of AF during AMI
carried an increased risk of developing in-hospital re-infarction,
cardiogenic shock, heart failure, and asystole. Importantly, the
presence of AF of new onset during AMI carried an increased
risk of in-hospital, 30-day, 1-year, and 3-year mortality, whereas
pre-existing AF did not appear to carry any such risk.
7–9Increased
risk included both sudden and non-sudden cardiac death. Some
evidence was reported regarding the independent signiﬁcance of
short-lasting vs. long-lasting AF episodes. The independent value
of AF as a predictor of mortality was not substantiated in all
trials, which raises doubts about the impact of AF therapies on
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10 Also the risk of stroke was signiﬁcantly increased in AF
patients. Similar to mortality, stroke risk was increased in hospital,
at 30 days, and during intermediate follow-up. Use of oral anticoa-
gulation, which in this population needs to be integrated with anti-
platelet agents, appeared to provide additional protection within
early follow-up and not always in prospective series.
11,12 Finally,
the authors report on the lack of consistent data with regards to
the impact of anti-arrhythmic therapies to terminate or control
AF in the setting of AMI.
By outlining the many uncertainties still existing in the ﬁeld of AF
complicating AMI, the study of Schmitt et al.
1 offers a clue to which
questions are in most urgent need of an answer in the near future
and provides suggestions on how they should best be approached.
How should AF during AMI be
interpreted?
The appearance of AF in the setting of AMI should raise two levels
of concern, one related to the impact on the current clinical con-
dition and the other related to the prognostic implications that AF
may have. In AMI patients developing AF, assessment of the clinical
proﬁle should be performed inclusive of pre-existing co-morbidity
(quality and entity), site and extent of MI, site of culprit lesion,
impairment of LV function, impact of reperfusion, tolerability to
and effects of b-blockers, ACE, and AT II inhibitors (or reasons
preventing drug administration), blood electrolytes, hormones,
and pO2, pCO2, and pH levels.
The deﬁnition of the patient’s clinical proﬁle is not only valuable
to guide therapies which may contribute to revert rhythm disturb-
ances, but would also serve to categorize patients with AF more
accurately. For example, patients with AF in the absence of LV dys-
function (i.e. those with successful reperfusion therapy or little
myocardial damage) and pre-existing AF may represent a different
population compared with patients with AF of new onset and with
signiﬁcant LV dysfunction. In these subgroups, similar therapies
may lead to opposite effects. Another example is given by the dur-
ation of AF and its tendency or not to recur. Similarly, patients with
other characteristics could fall into identiﬁable subgroups.
The role that subgroup identiﬁcation may play in generating
observational data is intuitive and may help to understand contra-
dictory literature data better, as well as to individualize treatment
strategies or re-deﬁne prognostic implications based on different
patient characteristics. One example related to the prognostic
implication in AF subgroups is given by the need for long-term
oral anticoagulants. While there is some evidence that this
therapy may protect from early and late thromboembolic risk, it
is not clear whether the beneﬁt could be extended to the entire
population or to subgroups with recurrent paroxysmal AF, signiﬁ-
cant asymptomatic arrhythmic burden episodes of longer duration,
drug-refractory AF, or post-discharge AF.
How should AF during AMI be
treated and prevented?
Early reperfusion and anticoagulation strategies represent the cor-
nerstone of all therapies in patients with AMI and are likely to
reduce, probably by  50%, the risk of developing AF and to
protect against the associated thromboembolic risk. A further con-
tribution to limit the risk of developing AF is the use of b-blockers,
ACE inhibitors, and AT II inhibitors.
13,14 The mechanism by which
these drugs prevent AF is most probably related to their capacity
to limit the changes in the substrate produced by ischaemia of the
culprit artery, although they can also have a direct effect on the
arrhythmic substrate.
Once AF has occurred, compensation of haemodynamic or elec-
trolyte imbalance with the use of anti-hypertensive or anti-
hypotensive agents and electrolyte infusion should be aimed for,
when appropriate. Restoration of haemodynamic and electrolyte
balance may not only favour spontaneous restoration of sinus
rhythm, but may also contribute to the maintenance of sinus rhythm
following electrical cardioversion. Although difﬁcult to obtain, categ-
orization of patients based on the presence or absence of transient
precipitating factors, response to compensating manoeuvres, need
for and response to electrical cardioversion, and presence or
absence of concomitant LV dysfunction would serve to aid in the
interpretation of the independent role of AF in patient prognosis.
Control of ventricular rate is an acceptable alternative to
sinus rhythm restoration, but the use of b-blockers, digoxin, and
calcium antagonists should be considered in light of their potential
negative inotropic effect and increased oxygen consumption. It is
of importance that the prognostic implications of selecting a
‘rhythm vs. rate control’ strategy in the setting of AF complicating
AMI have not been investigated as early restoration of sinus
rhythm might have some potential beneﬁt in this patient population.
In addition to electrical cardioversion, usually preferred under
conditions of AF-related imbalance of patient haemodynamics,
amiodarone can be used for restoration of sinus rhythm. This
drug is usually preferred to other antiarrhythmic agents because
of its limited negative inotropic effect. Data are lacking with
regard to the comparative efﬁcacy of amiodarone vs. placebo in
restoring sinus rhythm during the early phase of AMI, the role of
other anti-arrhythmic agents in patients with AF and well preserved
LV function, and whether early and stable restoration of sinus
rhythm carries an independent prognostic beneﬁt. It would be
important to identify risk predictors for development of AF in the
setting of AMI. Identiﬁcation of patients at high risk might allow pro-
phylactic anti-arrhythmic strategies to be devised and for them to be
assessed in the in-hospital and long-term prognosis of patients.
Protection from early and late thromboembolic risk in AF
patients is currently left to unfractionated heparin and to oral
anticoagulants in addition to clopidogrel, respectively. However,
more solid data are required to establish the need for long-term
oral anti-coagulants, particularly in patients with well preserved
or well restored LV function, single in-hospital short-lasting AF,
and low CHADS2 score.
In summary, the onset of AF in the setting of AMI represents a
warning event requiring immediate intervention. The mode of
intervention inﬂuences the short-term outcome and may have
implications for long-term patient outcome. Selection of the best
therapies and interpretation of their effect is often limited by our
inability to discriminate among the several variables in play and
by lack or inconsistency of data according to evidence-based
medicine. With this perspective in mind, efforts should be made
Editorial 1036to provide better patient categorization in ongoing trials. The level
of information generated through this methodology will probably
help to discriminate among variables in play, to improve interpret-
ation of currently available data, and to generate studies addressing
unsolved issues in this crucial ﬁeld of medicine.
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